Vascepa is a prescription medication that contains the active ingredient icosapent ethyl, which is used to reduce the risk of cardiovascular events such as heart attack and stroke in certain adult patient groups. According to the FDA, Vascepa is approved for use in adults with established cardiovascular disease or diabetes and two or more additional risk factors for cardiovascular disease [2].

The drug is not approved for all types of patients, as it is specifically indicated for those who meet the criteria outlined above. It is important to note that Vascepa is not intended to be a substitute for a healthy lifestyle and should be used in conjunction with a proper diet and exercise regimen [3].

In addition, the patent for Vascepa is set to expire in 2030, after which generic versions of the drug may become available [1].

Sources:
[1] https://www.drugpatentwatch.com/p/tradename/VASCEPA
[2] https://www.fda.gov/news-events/press-announcements/fda-approves-use-drug-reduce-risk-cardiovascular-events-certain-adult-patient-groups
[3] https://www.vascepa.com/